On December 23, the General Office of the National Development and Reform Commission released the 2019 evaluation results of the National Enterprise Technology Center. Among the 1,563 participating companies, CSPC was rated "excellent" with a score of 91.3, ranking it among the best in the industry. .
As the highest level of China's enterprise technology center rating, the National Enterprise Technology Center is jointly identified and guided by the National Development and Reform Commission, the Ministry of Science and Technology, the Ministry of Finance, the General Administration of Customs, and the State Administration of Taxation. Leading large-scale demonstration and qualified enterprise technology centers are recognized, encouraging and guiding key industry enterprises to drive industrial technological progress and innovation capabilities, give play to the main role of enterprises in technological innovation, and establish and improve the institutional mechanisms for enterprise-led industrial technology research and innovation.
CSPC Holdings Group Co., Ltd. is a national-level innovative enterprise integrating the research and development, production and sales of innovative drugs. It has 8 national-level R & D platforms, 6 provincial-level R & D platforms, and 376 valid invention patents. In the last three years, 18 international, national and industry standards have been presided over and participated in the formulation, and 175 research and development projects have been conducted by enterprises.
At present, CSPC has established an integrated R & D system at home and abroad, with R & D and clinical centers in Shijiazhuang, Beijing, and Shanghai, and clinical offices in Wuhan, Shenyang, and other cities; in California, Texas, USA There are R & D centers and clinical centers in four places, including New Zealand and New Jersey. The annual investment in R & D exceeds 2 billion yuan. At present, the Group has about 300 innovative drug product projects, including more than 50 new target large molecular biological drugs, more than 40 new small molecular drugs, more than 20 new formulations, and more than 50 clinical research projects.
The evaluation of the National Enterprise Technology Center in 2019 is a recognition of CSPC's innovation strength. The dawn of 2020 is coming. CSPC will continue to strengthen innovation to become a globally respected and respected innovative pharmaceutical company. And work harder!